Day: August 31, 2023

Gaming and Leisure Properties, Inc. Declares an Increased Third Quarter 2023 Cash Dividend of $0.73 Per Share

Written by Customer Service on August 31, 2023. Posted in Dividend Reports And Estimates.

WYOMISSING, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (the “Company”), announced today that, at its meeting yesterday, the Company’s Board of Directors has declared the third quarter 2023 cash dividend of $0.73 per share of its common stock, an increase from the second quarter of $.01 per share per quarter. The dividend is payable on September 29, 2023 to shareholders of record on September 15, 2023. The third quarter 2022 cash dividend was $0.705 per share of the Company’s common stock. While the Company intends to pay regular quarterly cash dividends for the foreseeable future, all subsequent dividends will be reviewed quarterly and declared by the Board of Directors at its discretion. About Gaming and Leisure Properties GLPI is engaged in the business of acquiring, financing, and...

BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast Cancer

Written by Customer Service on August 31, 2023. Posted in Public Companies.

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has accepted a letter of intent from Dr. Massimo Cristofanilli, Director of Breast Medical Oncology and Associate Director of Precision Medicine in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, outlining the parties’ plans and commitment, upon regulatory approval, to initiate a Phase 2 investigator-initiated clinical study to evaluate BriaCell’s novel immunotherapy, Bria-IMT™, in combination with a check point inhibitor (CPI), in early stage, newly diagnosed, high-risk triple negative breast cancer (TNBC) patients...

Thumzup® to Present at The New York Venture Summit on September 7, 2023

Written by Customer Service on August 31, 2023. Posted in Public Companies.

Thumzup Media CorporationThumzup AppAvailable in the App Store and Google Play, Thumzup Enables Virtually Everyone to Earn Cash Rewards for Posting on Social Media about the Brands They Love Los Angeles, CA, Aug. 31, 2023 (GLOBE NEWSWIRE) — Thumzup Media Corporation (“Thumzup” or the “Company”) (OTCQB: TZUP) is excited to announce that its founder and Chief Executive Officer, Robert Steele, will be presenting at The New York Venture Summit (the “Summit”) on September 7, 2023 at 11:40am EDT. The Summit event is aimed at connecting fast-growing, emerging-growth companies with active venture capitalists, corporate investors, private investors, investment bankers, and strategic partners. We believe that Thumzup is ripe to be considered by the Summit’s attendees. The Thumzup mobile app, which is available...

Xometry to Participate in Upcoming Investor Conferences

Written by Customer Service on August 31, 2023. Posted in Public Companies.

NORTH BETHESDA, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ:XMTR), the global AI-powered marketplace connecting enterprise buyers with suppliers of manufacturing services, today announced that management will attend the following investor events:Goldman Sachs Communacopia + Technology Conference Sept. 5, in San Francisco at 2:25 p.m. P.T. Citi’s 2023 Global Technology and GEMS Conference, Sept. 7, in New York at 11:15 a.m. E.T. CL King’s 21st Annual Best Ideas Conference 2023, Sept. 18, (virtual event with no webcast)Webcasts and replays of the fireside chats will be accessible within the Investor Relations section of Xometry’s website following each session. About Xometry Xometry’s (NASDAQ:XMTR) AI-powered marketplace, popular Thomasnet industrial sourcing platform and suite of cloud-based services are rapidly...

Pardes Biosciences Announces Closing of Tender Offer

Written by Customer Service on August 31, 2023. Posted in Public Companies.

CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes’ outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent value right (each, a CVR and each CVR together with the Cash Amount, the Offer Price) associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property. The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on August 30, 2023 (the Expiration Date). As...

Asset Performance Management Market Size to Surpass USD 7.99 Billion by 2030, exhibiting a CAGR of 14.6%

Written by Customer Service on August 31, 2023. Posted in Mergers And Acquisitions.

As per the report by Fortune Business Insights, the Asset Performance Management Market size is projected to reach USD 7.99 billion in 2030, at a CAGR of 14.6% during the forecast period, 2023-2030Asset Performance Management MarketForecast, 2023 – 2030Pune, India, Aug. 31, 2023 (GLOBE NEWSWIRE) — Global asset performance management market size was valued at USD 2.75 billion in 2022 and is projected to reach USD 7.99 billion by 2030, exhibiting a CAGR of 14.6% over the estimated period. Fortune Business Insights presents this information in their report titled “Global Asset Performance Management Market Forecast, 2023-2030.”Request a Sample PDF: https://www.fortunebusinessinsights.com/enquiry/sample/asset-performance-management-market-100496Key Industry Development: March 2022 – AVEVA announced a collaboration...

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

Written by Customer Service on August 31, 2023. Posted in Mergers And Acquisitions.

Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase of Acer’s secured debt in capital efficient structure Zevra to assume commercialization efforts of OLPRUVA™, recently approved for the treatment of urea cycle disorders (UCDs) FDA-approved commercial asset expected to increase and diversify Zevra’s revenues OLPRUVA™ commercial operations provide Zevra scale and cost synergies to complement the potential launch of arimoclomol Adds EDSIVO™, a Phase 3 program for vascular Ehlers-Danlos Syndrome (vEDS), to Zevra’s rare disease clinical pipeline Zevra to discuss details during conference call today, at 8:30 a.m. ET CELEBRATION, Fla. and NEWTON, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra”), a rare disease...

Veterinary Diagnostics Market Size to Surpass USD 14.48 billion by 2030, exhibiting a CAGR of 10.7%

Written by Customer Service on August 31, 2023. Posted in Mergers And Acquisitions.

As per the report by Fortune Business Insights, the global Veterinary Diagnostics Market size is projected to reach USD 14.48 billion in 2030, at a CAGR of 10.7% during the forecast period, 2023-2030Veterinary Diagnostics MarketVeterinary Diagnostics Market (2023-2030)Pune, India, Aug. 31, 2023 (GLOBE NEWSWIRE) — The veterinary diagnostics market size was valued at USD 6.49 billion in 2022 and the market is anticipated to expand USD 14.48 billion by 2030, exhibiting a CAGR of 10.7% during forecast period. The rise is propelled by the increasing establishment of new diagnostic laboratories and rising pet insurance demand. Fortune Business Insights™ provides this information in its research report, titled “Veterinary Diagnostics Market, 2023-2030”.Request a Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/veterinary-diagnostics-market-101040Key...

illumin Announces Final Results of Substantial Issuer Bid

Written by Customer Service on August 31, 2023. Posted in Public Companies.

TORONTO and NEW YORK, Aug. 31, 2023 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX:ILLM, Nasdaq:ILLM) (“illumin” or the “Corporation”) today announced the final results of its substantial issuer bid (the “Offer”), which expired at 5:00 p.m. (Eastern Time) on August 30, 2023. Under the Offer, the Corporation has purchased for cancellation 4,593,200 of its common shares (“Shares”) at a purchase price of C$2.65 per Share, for an aggregate purchase price of approximately C$12,171,980. Shares purchased under the Offer represent approximately 8.18% of the issued and outstanding Shares at the time that the Offer was commenced. Immediately following the completion of the Offer and having taken into account the cancellation of the Shares purchased pursuant to the Offer, 51,592,431 Shares are now issued and outstanding. Canaccord Genuity...

Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors

Written by Customer Service on August 31, 2023. Posted in Public Companies.

Pleasanton, CA, Aug. 31, 2023 (GLOBE NEWSWIRE) — Peak Bio, Inc. (“Peak Bio” or the “Company”) (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases. We are pleased to announce the appointment of one new independent board member, Michael Friedman, MBA as a Class III Director and as a member of the Company’s Audit Committee and Compensation Committee. “Our Board of Directors is comprised of an experienced and dedicated team of biotech leaders committed to advancing our portfolio of clinical-stage assets and preclinical platform programs. We are excited to channel Michael’s talent, breadth of experience, expertise, and energy into furthering our mission and continue to strengthen our...

Day: August 31, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice